The ability of liposomes bearing anti-HLA-DR FabP fragments at the end termini of polyethyleneglycol chains (sterically stabilized immunoliposomes) to target HLA-DR expressing cells and increase the accumulation of liposomes into lymphoid organs has been evaluated and compared to that of conventional liposomes, sterically stabilized liposomes and conventional immunoliposomes after a single subcutaneous injection to mice. The accumulation of sterically stabilized liposomes in lymph nodes was higher than that of conventional liposomes. Sterically stabilized immunoliposomes accumulated much better than conventional immunoliposomes in all tissues indicating that the presence of PEG has an important effect on the uptake of immunoliposomes by the lymphatic system. Fluorescence microscopy studies showed that sterically stabilized liposomes are mainly localized in macrophage-rich areas such as the subcapsular region of lymph nodes and in the red pulp and marginal zone of the spleen. In contrast, sterically stabilized immunoliposomes mostly accumulated in the cortex in which follicles are located and in the white pulp of the spleen. As the human HLA-DR determinant of the major histocompatibility complex class II is expressed on activated CD4+ T lymphocytes and antigen presenting cells such as monocyte/macrophages and dendritic cells, known as the cellular reservoirs of HIV-1, liposomes bearing anti-HLA-DR antibodies constitute an attractive approach to concentrate drugs in HIV-1 reservoirs and improve their therapeutic effect. ß
Introduction
It is well established that lymphoid tissues are the major reservoirs of human immunode¢ciency virus type-1 (HIV-1) [1^5] . During primary infection, HIV-1 particles disseminate rapidly in the lymphoid organs where they replicate actively in CD4+ T-cells.
In the period of clinical latency, HIV-1 becomes trapped onto the follicular dendritic cell (FDC) network, located in the germinal centers of the secondary lymphoid organs, and persistently infects activated CD4+ T-cells [6] . In the advanced stage of the disease, the microenvironment network within the germinal centers is destroyed, and the incapacity of FDC to retain HIV-1 particles has been postulated to contribute to the increased viral burden in the periphery [1] . As peripheral lymphoid tissues play a crucial role in e¡ective immune response, it is im-portant to reduce or abrogate the production and the accumulation of HIV-1 particles in these tissues to preserve both their architecture and integrity.
Fortunately, highly active antiretroviral therapy (HAART), usually consisting in the combination of two nucleoside analogues and one protease inhibitor, has been shown to markedly diminish the number of HIV-1 RNA copies in secondary lymphoid tissues [7^9] . However, replication-competent HIV-1 was routinely isolated from resting CD4+ T-cells, even after 30 months of HAART, impairing the possibility to stop the treatment [8^14] . Increasing numbers of treatment failures resulting from toxicity, drug-resistant mutants and poor compliance of patients to drug regimen are emerging with long-term therapy [15] . Consequently, strategies aimed at reaching therapeutic levels of drugs into the lymphoid organs should be developed to improve the e¤cacy of antiretroviral agents and to prevent suboptimal concentrations of drugs within infected cells that could potentially lead to the development of resistance.
As liposomes are naturally taken up by cells of the mononuclear phagocyte system (MPS), liposomebased therapy represents a convenient approach to improve the delivery of drugs into lymphoid tissues [16^19] . Morphological observations on the fate of liposomes in regional lymph nodes suggest that liposomes remained stable within the lymphatic circulation and that they eventually enter into cells of the lymph nodes by phagocytosis to end up in the lysosomal apparatus [20] . On the other hand, the coupling of polyethyleneglycol (PEG) chains on the surface of liposomes (sterically stabilized liposomes) was shown to increase their ability to move through the lymph after subcutaneous injection and to decrease their rate of uptake by the MPS, increasing their residence time within plasma and/or lymph [21, 22] . Consequently, attachment of antibodies to sterically stabilized liposomes represents an attractive strategy to combine prolonged circulation time and e¤cient delivery of therapeutic drugs to speci¢c cell population and/or pathogen.
FDC, B lymphocytes, activated CD4+ T-cells and antigen presenting cells like macrophages are abundant in lymphoid tissues and all express substantial levels of the HLA-DR determinant of the major histocompatibility complex class II (MHC-II). In addition, it is well known that many enveloped viruses, including HIV-1, acquire host cell surface molecules during the budding process. It has been reported that the HLA-DR determinant is physically present on the virion surface and constitutes one of the most abundant host-derived molecules carried by HIV-1 [23, 24] . Liposomes bearing surface-attached anti-HLA-DR antibodies thus constitute an interesting approach to target speci¢cally HIV-1 reservoirs as well as free HIV-1 particles trapped in the FDC network. In the present study, the ability of liposomes bearing anti-HLA-DR FabP fragments at the end termini of PEG chains (sterically stabilized immunoliposomes) to target HLA-DR expressing cells and increase their accumulation in secondary lymphoid organs has been evaluated and compared to that of conventional liposomes, sterically stabilized liposomes and conventional immunoliposomes.
Materials and methods

Materials
Dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidylglycerol (DPPG) and distearoylphosphatidylethanolamine-N-[poly(ethyleneglycol)-2000] (DSPE-PEG) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Dipalmitoylphosphatidylethanolamine-N-(4-(p-maleimidophenyl)butyryl) (DPPE-MPB) was purchased from Northern Lipids (Vancouver, BC, Canada) and distearoylphosphatidylethanolamine-[poly(ethyleneglycol)2000]-N-(4-(p-maleimidophenyl)butyryl) (DSPE-PEG-MPB) was custom-synthesized by Shearwater Polymers Inc. (Huntsville, AL, USA). [ 3 H]cholesterylhexadecylether was purchased from NEN Life Science Products (Boston, MA, USA). 1,1P-dioctadecyl-3,3,3P,3P-tetramethylindocarbocyanine perchlorate (DiI) was purchased from Molecular Probes (Eugene, OR, USA). Lysyl endopeptidase obtained from Achromobacter lyticus was purchased from Wako Chemicals (Richmond, VA, USA).
Preparation of antibodies
Monoclonal antibodies IgG 2b (clone Y-17, clone OKT4, ATCC, Rockville, MD, USA) that react with I-E subregion products (murine HLA-DR) or human CD4 was isolated from ascites £uids and puri¢ed using a protein G a¤nity column ( 
Preparation of F(abP) 2 fragments
The F(abP) 2 fragments were produced following incubation of the antibody (5 mg/ml) with lysyl endopeptidase (in 50 mM Tris^HCl, pH 8.5) in a 1:50 enzyme/substrate molar ratio for 2 h at 37³C. Lysyl endopeptidase cleaved IgG 2b at Lys-228E/Cys-229 without perturbing the disul¢de bridges. The digestion products contained undigested IgG, F(abP) 2 and Fc fragments. The enzyme was removed by gel chromatography on a Sephadex G-25M column (Pharmacia, Baie d'Urfë, QC, Canada). Fractions containing digestion products were determined using a BCA protein assay reagent kit (Pierce, Rockford, IL, USA) and pooled together. F(abP) 2 fragments were separated with a protein A a¤nity chromatography column (Pharmacia, Baie d'Urfë, QC, Canada). The column retained Fc fragments and undigested IgG 2b whereas F(abP) 2 fragments were collected. F(abP) 2 fragments (110 kDa) were then concentrated using Centricon-50 (Amicon, Beverly, MA, USA) and resuspended in 1 ml phosphate EDTA bu¡er (100 mM sodium phosphate and 5 mM EDTA, pH 6.0).
Preparation of FabP fragments
F(abP) 2 fragments were incubated with 6 mg of 2-mercaptoethylamine^HCl (0.05 M) for 90 min at 37³C. This product cleaved the disul¢de bridges between the heavy chains but preserved the disul¢de linkages between the heavy and light chains. The solution was eluted on a Sephadex G-25M column pre-equilibrated with acetate^EDTA bu¡-er (100 mM anhydrous sodium acetate, 88 mM sodium chloride and 1 mM EDTA, pH 6.5) and FabP fragments were collected in 1 ml fractions. Fractions containing FabP fragments were determined using a BCA protein assay (Pierce, Rockford, IL, USA) and pooled together. The FabP fragments (55 kDa) were concentrated using Centricon-10, resuspended in acetate^EDTA bu¡er and kept under nitrogen atmosphere at 4³C until coupling to liposomes. Fig. 1 shows a schematic representation of the different liposomal formulations used in this study. Liposomes composed of DPPC/DPPG/DPPE-MPB (10:3:0.33 mol/mol) for immunoliposomes and DPPC/DPPG/DSPE-PEG-MPB (10:3:0.83 mol/ mol) for sterically stabilized immunoliposomes were prepared according to the method of thin lipid ¢lm hydration. In brief, the lipid mixture was dissolved in chloroform in a round-bottomed £ask and the organic solvent was evaporated to form a thin lipid ¢lm. In some experiments, [ 3 H]cholesterylhexadecylether (0.3 WCi/Wmol lipid) was added as a radioactive tracer. The lipid ¢lm was then hydrated with acetate^EDTA bu¡er (pH 6.5). Multilamellar vesicles were sequentially extruded through 0.2 and 0.1 Wm polycarbonate membranes (Nuclepore, Cambridge, MA, USA) using a stainless steel extrusion device (Lipex Biomembranes, Vancouver, BC, Canada). The mean vesicle size of the liposomes, as evaluated with a submicron particle analyzer (Coulter Electronics, Hialeah, FL, USA), was between 100 and 118 nm. The ¢nal concentration of liposomes was determined using an enzymatic colorimetric method (phospholipids B kit, Wako Chemicals, Richmond, VA, USA). Conventional liposomes were prepared as above except that no DPPE-MPB was incorporated in the lipid composition. In the case of sterically stabilized liposomes, DSPE-PEG-MPB was replaced by DSPE-PEG.
Preparation of (immuno)liposomes
Coupling reaction
Freshly prepared liposomes were incubated with freshly prepared FabP fragments (35 Wg FabP/Wmol lipid) overnight at 4³C under continuous agitation and under nitrogen atmosphere. Liposomes bearing surface-attached antibodies (immunoliposomes) were separated from unconjugated FabP fragments by ultracentrifugation (100 000Ug, two times for 45 min at 4³C) and immunoliposomes were resuspended in PBS (pH 7.4). The total amount of FabP conjugated to liposomes (5^15 Wg/Wmol of lipids) was evaluated with the Coomassie protein assay reagent (Pierce, Rockford, IL, USA). The speci¢city and a¤nity of immunoliposomes toward the antigen has been previously demonstrated [25] .
In vitro binding and speci¢city of immunoliposomes
The binding and speci¢city of sterically stabilized liposomes and immunoliposomes were evaluated on freshly prepared C3H mouse spleen cells by £ow cytometry assay. In brief, suspension of cells (10 6 cells/ ml) was incubated with 1.5 Wmol of DiI-labeled conventional liposomes, immunoliposomes, sterically stabilized liposomes or immunoliposomes. Samples were washed and resuspended in PBS. The speci¢city of liposomes for cells was determined by £ow cytometry from the £uorescence associated to DiI (£uo-rochrome incorporated into the lipid membrane). Controls consisted of a commercial biotinylated Y-17 antibody (Cederlane Laboratories Ltd, Hornby, ON, Canada) and a isotype-matching irrelevant murine monoclonal antibody (OKT4) or FabP fragment coupled to conventional liposomes or sterically stabilized liposomes. No decrease in speci¢city of immunoliposomes (conventional or sterically stabilized) was observed for up to 3 weeks as revealed by £ow cytometry analysis.
Tissue distribution
A single bolus injection of conventional liposomes, sterically stabilized liposomes, conventional immunoliposomes or sterically stabilized immunoliposomes (2 Wmol lipids/500 Wl) was administered subcutaneously in the upper back below the neck of female C3H mouse (18^20 g; Charles River Breeding Laboratories, St-Constant, QC, Canada). At speci¢c time points, animals were killed and blood was collected and the plasma was separated by centrifugation (6000Ug for 10 min at 4³C). At the same time, selected tissues were collected, washed in PBS and weighed. Tissues and plasma were then treated with Beckman tissue solubilizer (Beckman Instruments Inc., Irvine, CA, USA) and decolored with H 2 O 2 . Lipid levels in all samples were monitored by scintillation countings. Six animals per group were used for each time point. 
Liposome £uorescent labeling
Liposomal lipids (2.5 mg/ml) were incubated with 10 Wg/ml of DiI under darkness for 1 h at 60³C with agitation. Unbound DiI was removed by centrifugation (300Ug for 15 min at 4³C) of 1 ml of the liposomal preparation through a 10 ml coarse Sephadex G-50 column.
Tissue preparation for optical microscopy
A single bolus injection of sterically stabilized liposomes and sterically stabilized immunoliposomes (2 Wmol lipid/500 Wl) was administered subcutaneously in the upper back below the neck of female C3H mice. At speci¢c time intervals post-injection, animals were killed and tissues (spleen, brachial and cervical lymph nodes) were removed. Tissues were washed in PBS, embedded in OCT Tissues Tek (Bayer, Pointe-Claire, QC, Canada), frozen in liquid nitrogen and stored at 320³C. Tissue sections (10 Wm thick) were cut using a Jung Frigocut 2800E (Leica Canada Inc., St-Laurent, QC, Canada) and deposited on slides pretreated with 2% aminoalkysilane. Coated slides were immediately observed with a Nikon Micro£ex HFX-DX £uorescence microscope. DiI £uorescence was observed with a rhodamine optic excitation ¢lter (ex: 510^560 nm, dichroic mirror: DM 580 and barrier ¢lter: BA 590). A minimum of three tissues from di¡erent animals was used for each time point.
Statistical analysis
All statistical analyses were performed using a computer package (Statview+SE Software, Abacus Concepts, Berkeley, CA, USA). The signi¢cance between groups was statistically evaluated using a oneway analysis of variance (ANOVA) test, followed by t-test with Fisher's corrections. 
Results
In vitro binding of sterically stabilized immunoliposomes
Tissue distribution
In order to evaluate if the presence of PEG molecules on the surface of liposomes can prolong their circulation time and increase their rate of lymphatic uptake, we have ¢rst evaluated the tissue distribution of sterically stabilized and conventional liposomes following a single subcutaneous injection in the upper back of C3H mice. Table 1 shows the area under the curve of the concentration of sterically stabilized and conventional liposomes in di¡erent tissues after a period up to 240 h post-injection (time points 24, 48, 120 and 240 h). Results show that the accumulation of both liposome formulations was greater in lymph nodes near the injection site (e.g. cervical and brachial lymph nodes) when compared to other nodes or tissues. Moreover, sterically stabilized liposomes accumulated more e¤ciently than conventional liposomes in all lymph nodes as well as in liver and spleen. Although very low, the accumulation of sterically stabilized liposomes in plasma was similar to that of conventional liposomes. It can be speculated that the enhanced accumulation of sterically stabilized liposomes in these tissues may be due to their reduced accumulation at the injection site and their prolonged circulation time in the lymphatic system which increase their uptake by lymphoid tissues.
We have next determined if the presence of anti-HLA-DR FabP fragments at the end termini of PEGcoated liposomes could also improve their tissue accumulation compared to PEG-free immunoliposomes. Once again, results show that the concentration of both immunoliposomal formulations was higher in brachial and cervical lymph nodes than in other tissues suggesting that liposomes administered subcutaneously accumulated preferentially in the regional lymph nodes (Fig. 3) . In addition, sterically stabilized immunoliposomes targeted more e¤ciently all tissues, with a peak of accumulation at 240 h in Fig. 3 . Tissue distribution of conventional immunoliposomes (dotted bar) and sterically stabilized immunoliposomes (solid bar) in brachial, cervical, mesenteric, inguinal and popliteal lymph nodes, and spleen following a single subcutaneous injection to mice. Values represent the mean ( þ S.E.M.) obtained for six animals per group per time point. *, and **, signi¢cantly di¡erent (P 6 0.05) and (P 6 0.01), respectively when compared to conventional immunoliposomes.
brachial, inguinal and popliteal lymph nodes. The concentration of sterically stabilized immunoliposomes in mesenteric lymph nodes reached a plateau at 24 h post-injection and the tissue distribution pro¢le was very similar to that observed in the spleen. There were no signi¢cant di¡erences in the accumulation of sterically stabilized and conventional immunoliposomes at 6 h post-injection in lymph nodes and spleen, except for the popliteal lymph nodes, which are the farther lymph nodes from the injection site. The radioactive tracer in liposomes remained stable for the time period of the experiment (data not shown). Table 2 shows the area under the curve of sterically stabilized and conventional immunoliposomes in di¡erent tissues. Results clearly demonstrated that sterically stabilized immunoliposomes accumulated much better than conventional immunoliposomes in all tissues indicating that the presence of PEG has an important e¡ect on the uptake of immunoliposomes by the lymphatic system.
In another set of experiments, the concentration of the four types of liposomes was determined at 48 and 120 h after their subcutaneous administration to C3H mice. Fig. 4 shows that the presence of PEG on the surface of liposomes or immunoliposomes had no signi¢cant e¡ect on their accumulation in the regional lymph nodes (brachial and cervical) but signi¢cantly increased their uptake in other lymph nodes compared to conventional liposomes or immunoliposomes. On the other hand, there was no signi¢cant di¡erence in the accumulation of sterically stabilized liposomes in the spleen when compared to conventional liposomes at these two time points. In contrast, the concentration of sterically stabilized immunoliposomes in this tissue was much higher when compared to conventional immunoliposomes. In addition, the presence of anti-HLA-DR FabP fragments on both conventional and sterically stabilized liposomes greatly improved their accumulation in regional lymph nodes when compared to non-targeted liposomes. The presence of an irrelevant isotypematching FabP fragment on sterically stabilized liposomes had no e¡ect on the tissue distribution pro¢le being similar to that of sterically stabilized liposomes (data not shown).
Tissue localization
Since sterically stabilized liposomes and sterically stabilized immunoliposomes represent the best formulation to target lymphoid tissues, we have next evaluated if the presence of anti-HLA-DR FabP fragments at the end termini of PEG chains a¡ects the tissue localization of liposomes. No signi¢cant £uorescent signal was observed in the subcapsular area of the lymph nodes when nonspeci¢c isotype-matching FabP fragments were coupled to sterically stabilized liposomes. Fig. 6 compared the localization of sterically stabilized liposomes and sterically stabilized immunoliposomes in the spleen at 48 h after their subcutaneous administration in mice. Results show that the accumulation of sterically stabilized immunoliposomes in this tissue is more important than that of sterically stabilized liposomes and that their localization is di¡erent. However, it should be noted that tissue localization studies using the £uorescent marker are qualitative and could not be used to evaluate the concentration of liposomes in these tissues. In the case of sterically stabilized liposomes, a weak £uorescence signal was observed in the marginal zone of the white pulp. In contrast, sterically stabilized immunoliposomes were largely concentrated in the lymphoid nodules of the white pulp and little in the marginal zone. The administration of free DiI did not result in any £uorescent signal in all studied tissues. Furthermore, the injection of DiI-labeled liposomes showed a disappearance of the £uorescent signal as a function of time indicating that the probe is eliminated with time. When non-speci¢c immunoliposomes were injected to mice, a weak £uorescence signal was observed in the same area than that observed for sterically stabilized liposomes suggesting that the presence of irrelevant antibody had no e¡ect on the tissue localization of liposomes.
Discussion
The introduction of triple drug therapy led to a lot of hope for the treatment of HIV-1 infection [26^29]. However, although this therapy can reduce the plasma viral load to undetectable levels, viral replication still occurs in the lymph nodes or other sanctuary sites of HIV-1 and this low viral level can lead to resistant mutations [10, 11, 26, 29, 30] . It was shown that initiation of HAART in infected individuals, as early as 10 days after the onset of symptoms of primary HIV-1 infection, did not prevent generation of latently infected resting CD4+ T-cells carrying integrated HIV-1 DNA despite the successful control of plasma viremia [31] . Since new anti-HIV-1 regimens do not eliminate the virus in the organism, a lifelong treatment is required. Problems associated with adherence to HIV-1 treatment and to side effects of triple combination therapy shed the light on the need of developing new e¤cient strategies [15, 27] .
One major advantage of liposomes as drug carriers is that their tissue distribution can be modulated through variations of their lipid compositions. It is thus possible to adapt the physicochemical properties of liposomal formulations according to the desired therapeutic objective. In the present study, the ability of di¡erent types of liposomes to target HLA-DR expressing cells and increase their accumulation in secondary lymphoid organs has been evaluated. The choice of the lipid compositions used in conventional liposomes and immunoliposomes was based on our previous studies showing that these formulations allowed e¤cient targeting of lymphoid tissues [25, 32] . The use of 6% PEG in sterically stabilized liposomes was selected as it was demonstrated that a 5^10 mol% concentration of PEG results in a maximum circulation time [33] . Moreover, we have used DSPE rather than DPPE because it was shown that proteins linked to DSPE anchors leave the membrane slower than DPPE [34] . In the case of sterically stabilized immunoliposomes, a proper control would have been to use liposomes containing 3.5% DSPE-PEG and 2.5% DSPE-PEG-MAL. However, studies performed in our laboratory showed that such formulation led to unfavorable coupling reaction, most likely because of the repulsive e¡ect of PEG chains for proteins.
Our results demonstrated that the subcutaneous injection of sterically stabilized liposomes bearing anti-HLA-DR FabP fragments represents an attractive approach to speci¢cally target the lymphoid tissues. The subcutaneous route of injection has been selected since it constitutes the most appropriate route for targeting lymph nodes [18, 21, 35] . In addition, it represents a simple route for patient self-administration and it might serve as a depot for the sustained release of drugs in vivo, reducing most likely the frequency of liposomal drug administration. However, mechanisms upon which liposomes reach lymph nodes are not well understood. It has been postulated that the sequestration of liposomes by these tissues could occur, either via a simple mechanical ¢ltration or by phagocytosis by cells of the reticuloendothelial system [35] . In the case of mechanical ¢ltration, it is important to use liposomes with a diameter less than 120 nm as it was shown that the fenestration by which ¢ltration occurs is via pores through such a diameter [21] .
The e¡ect of PEG molecules on the surface of liposomes has been extensively studied after intravenous injection. It was shown that PEG prolonged the circulation time of liposomes, reduced their uptake by mononuclear phagocyte system and increased their ability to cross in vivo biological barriers [36] . However, the e¡ect of steric stabilization of liposomes following subcutaneous administration is not well understood. It has been postulated that the presence of PEG could reduce the accumulation of liposomes at the site of injection and therefore increase their ability to move through the lymph [21, 22] . Our results have shown that the presence of PEG did not substantially increase the accumulation of liposomes in the regional lymph nodes as previously observed [37] . However, it signi¢cantly increased the accumulation of liposomes in lymph nodes far from the injection site, suggesting that the presence of PEG may reduce phagocytosis by cells of MPS increasing their e¤cacy to target other lymph nodes among the lymphatic vessels. As expected, the incorporation of PEG did not reduce the accumulation of liposomes in the spleen and liver.
Many coupling procedures of antibodies to sterically stabilized liposomes have been proposed in the literature [22,38^41] . In this study, anti-HLA-DR FabP fragments were covalently attached to DSPE-PEG-MPB via the interaction of sulfhydryl (FabP) and maleimide (MPB) groups. Thioether linkage is known to be one of the most useful and e¤cient reactions in bioconjugate chemistry. Moreover, we have used PEG 2000 because it allows e¤cient tissue targeting and high circulation half-lives [22] . Higher coupling e¤ciencies of FabP fragments to liposomes have been reported when FabP was attached at the terminal end of PEG chains [41, 42] . In our experiments, the FabP^liposomes coupling e¤ciency was in the range of 15^20% for both conventional and sterically stabilized liposomes, even if the concentration of MPB in sterically stabilized liposomes was higher than that of conventional liposomes (6% and 2.5%, respectively). These results suggest that the amount of MPB does not in£uence the coupling e¤ciency of FabP to the phospholipid vesicles. On the other hand, our results along with those of others [43] showed that the presence of free MPB on the surface of conventional or sterically stabilized liposomes does not in£uence attachment to cells in vitro or their tissue distribution.
Our data showed that anti-HLA-DR immunoliposomes accumulated better in brachial and cervical lymph nodes than that of conventional liposomes. However, the presence of anti-HLA-DR FabP fragments did not signi¢cantly enhance the liposomal accumulation in other lymph nodes. Although the coupling of FabP fragments rather than complete IgG is known to eliminate a range of Fc-mediated biological activities, like complement activation via the classical pathway and humoral responses of clearance via antibody^Fc receptor interactions, it is possible that conventional immunoliposomes are still rapidly taken up by cells of MPS present in lymph, impairing their possibility to target other lymphoid tissues far from the injection site. However, our results suggest that the attachment of FabP fragments at the end termini of PEG reduces the accumulation of liposomes at the injection site, diminishes their rapid uptake by cells of MPS and prolongs their circulation time improving their overall lymphatic uptake when compared to PEG-free immunoliposomes. This hypothesis is supported by the fact that a higher concentration of sterically stabilized immunoliposomes was observed in all lymph nodes studied, especially at late time points, in lymph nodes far from the injection site and in plasma. The higher concentration of sterically stabilized immunoliposomes in plasma when compared to conventional immunoliposomes could be attributed to the presence of PEG which reduces the binding of plasma proteins prolonging thereby their circulation time.
Fluorescence microscopy studies demonstrated that the localization of sterically stabilized anti-HLA-DR immunoliposomes in lymphoid tissues was completely di¡erent than that of sterically stabilized liposomes. In fact, sterically stabilized liposomes accumulated only in macrophage-rich areas such as the subcapsular region of lymph nodes and in the red pulp and marginal zone of the spleen. Oussoren et al. have observed the presence of colloidal gold particles in macrophages of regional lymph nodes following the subcutaneous administration of PEG-gold liposomes to mice [19] . It was hypothesized that because of the slow progression of liposomes through the lymph nodes, enough time was available for e¤cient interactions of the PEG liposomal surface with phagocytic cell membranes. In contrast, sterically stabilized immunoliposomes highly accumulated in the deep cortex of lymph nodes which contains aggregates of B-cells and FDCs constituting the follicles. In HIV-1 infection, FDCs, which reside in germinal centers, display HIV-1 particles on their surface to selectively activate B-cells. CD4+ T-cells from the paracortical area migrate to the germinal centers in response to B-cell activation to be eventually infected. Our results showed that sterically stabilized immunoliposomes highly accumulate in these regions and could represent a convenient strategy to deliver drugs in this area of the nodes inhibiting more e¤ciently HIV-1 replication. Moreover, the injection of sterically stabilized immunoliposomes resulted in an intense £uorescence signal in the white pulp of the spleen, suggesting a selective targeting of B-cells in the follicles and of macrophages present in the marginal zone surrounding the lymphoid follicle.
The use of sterically stabilized immunoliposomes could represent a convenient strategy to concentrate anti-HIV-1 drugs at sites of infection, more particularly within lymphoid organs. Such targeted delivery system should reduce the dissemination of HIV-1 and preserve the FDC microenvironment that will likely protect the infected host from developing the characteristic immunode¢cient state. The improved pharmacology of liposomal drugs could reduce the dose and frequency of administration of antivirals used in conventional therapy, facilitating drug compliance and limiting the occurrence of drug resistance. Given that HIV-1 particles acquire high amount of host-derived HLA-DR proteins, the encapsulation of destabilizing agents into sterically stabilized anti-HLA-DR immunoliposomes would be an interesting approach to target free viral particles trapped on FDC. The use of immunoliposomal drugs in HIV-1 therapy could hopefully o¡er new alternatives for the treatment of this retroviral infection.
